SCHEMBL13638256

SCHEMBL13638256

CCCCN(CCC)C(=O)OCC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 4/20 0.47
CA9 Q16790 4/20 0.47
CA1 P00915 3/20 0.47
MMP1 P03956 1/20 0.44
MMP2 P08253 1/20 0.44
MMP3 P08254 1/20 0.44
MMP8 P22894 1/20 0.44
SIGMAR1 Q99720 2/20 0.44
CA2 P00918 2/20 0.40
ALDH1A1 P00352 6/20 0.39
HPGD P15428 1/20 0.39
ALDH2 P05091 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
LMNA P02545 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4346470 0.96 CA12 (0.50) CA12CA9CA1MMP1MMP2
Hydrochloric Acid SCHEMBL28209960 0.94 CA12 (0.48) CA12CA9CA1MMP1MMP2
SCHEMBL10636394 0.92 CA12 (0.42) CA12CA9CA1MMP1MMP2
SCHEMBL5696536 0.92 CA12 (0.40) CA12CA9CA1MMP1MMP2
SCHEMBL5696589 0.92 CA12 (0.47) CA12CA9CA1MMP1MMP2
SCHEMBL10087947 0.91 CA12 (0.46) CA12CA9CA1CA2ALDH1A1
SCHEMBL8057883 0.90 CA12 (0.45) CA12CA9CA1MMP1MMP2
SCHEMBL25271571 0.89 CA12 (0.43) CA12CA9CA1MMP1MMP2
Hydrochloric Acid SCHEMBL28190002 0.89 CA12 (0.44) CA12CA9CA1SIGMAR1CA2
SCHEMBL28635538 0.88 CA12 (0.44) CA12CA9CA1MMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130096089-A1 Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders ALKERMES PHARMA IRELAND LIMITED 2013-04-18 US disclosed
US-7615651-B2 Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof PFIZER INC. (US) 2009-11-10 US disclosed
US-20080167371-A1 Diaryl, Dipyridinyl and Aryl-Pyridinyl Derivatives and Uses Thereof PFIZER INC. 2008-07-10 US disclosed
US-7365093-B2 Endothelin antagonists ABBOTT LABORATORIES (US) 2008-04-29 US disclosed
US-7208517-B1 Endothelin antagonists ABBOTT LABORTORIES (US) 2007-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096089-A1 Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders GABBR1, GABBR2, GABRE CA12 3134/4885CA9 3302/4885CA1 2576/4885
US-20080167371-A1 Diaryl, Dipyridinyl and Aryl-Pyridinyl Derivatives and Uses Thereof OPRD1, OPRK1, OPRL1 CA12 4859/4885CA9 4498/4885CA1 4566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.